Infectious Diseases

Pharmacokinetic and pharmacodynamic (PK-PD) modeling is more developed in the area of infectious disease pharmacotherapy than perhaps any other therapeutic specialty. The main reason for this is the ability to study the infectious agent outside of the patient. For instance, one can isolate Streptococcus pneumoniae, the pathogen associated with the greatest morbidity and mortality in community-acquired pneumonia, from the patient and then study the interaction between the drug and etiologic agent using PK-PD in vitro and in vivo model systems. Conversely, it is simply not as easy to remove diabetes mellitus from the patient and study it in the same manner.

ICPD scientists have extensive experience designing and analyzing data from PK-PD studies. From glassware to animal systems to humans, our study designs and analyses have led to better understandings of anti-infective pharmacology. Our expertise is regularly leveraged by pharmaceutical companies and others for candidate selection, exploring relationships between exposure and response in pre-clinical model systems, early dose regimen decision making, exposure-response analyses, susceptibility breakpoint decision-making and more. The results of our analyses are often central components of New Drug Applications and other regulatory submissions.